FDA-Approved Growth Factor
FDA-approved platelet-derived growth factor (PDGF) topical gel accelerates healing of diabetic foot ulcers extending into subcutaneous tissue. Regranex 0.01% becaplermin gel stimulates granulation tissue, cell proliferation, and wound closure when standard care fails. Medicare Part B covered mobile wound care in Beverly Hills, Orange County, Los Angeles, and all Southern California counties.
Regranex (becaplermin) is a recombinant human platelet-derived growth factor (PDGF-BB) gel approved by the FDA specifically for lower extremity diabetic neuropathic ulcers that extend into subcutaneous tissue or beyond.
PDGF is one of the body's natural wound healing signals. It stimulates fibroblast proliferation, angiogenesis (new blood vessel formation), and granulation tissue development—all critical for wound closure.
First topical growth factor approved for diabetic foot ulcers
Clinical studies show 30-50% improvement in healing rates
Reimbursed under Medicare Part B for qualifying ulcers
25+ Years of Use
Trusted since 1997
Stimulates fibroblast division and migration
Promotes new blood vessel formation
Accelerates formation of healthy wound bed
Promotes wound edges to contract and close
Debride and remove necrotic tissue, rinse with saline
Measured amount spread evenly over wound surface
Moist saline gauze covered with secondary dressing
Applied once daily for up to 20 weeks or until healed
Our specialists will evaluate if you're a candidate for growth factor therapy
Schedule Evaluation